Stage IV Rectal Cancer, Liver Metastasis, Resectable Clinical Trial
Official title:
Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases
Patients with rectal cancer and resectable liver metastases receive short course radiotherapy(5Gy/f x 5f) to the pelvis and XELOX consolidating chemotherapy al least 4 cycles after 2 weeks.
Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of
5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target
therapy) al least 4 cycles after 2 weeks.
After evaluation, patients with resectable rectal cancer and liver metastasis will undergo
surgery. Those patients with unresectable lesions will receive chemotherapy.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment